NL301203I2 - efgartigimod alfa - Google Patents
efgartigimod alfaInfo
- Publication number
- NL301203I2 NL301203I2 NL301203C NL301203C NL301203I2 NL 301203 I2 NL301203 I2 NL 301203I2 NL 301203 C NL301203 C NL 301203C NL 301203 C NL301203 C NL 301203C NL 301203 I2 NL301203 I2 NL 301203I2
- Authority
- NL
- Netherlands
- Prior art keywords
- efgartigimod
- alfa
- efgartigimod alfa
- Prior art date
Links
- 229940057042 efgartigimod alfa Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361920547P | 2013-12-24 | 2013-12-24 | |
PCT/US2014/072087 WO2015100299A1 (en) | 2013-12-24 | 2014-12-23 | Fcrn antagonists and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
NL301203I1 NL301203I1 (nl) | 2022-11-09 |
NL301203I2 true NL301203I2 (nl) | 2023-05-24 |
Family
ID=52347464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL301203C NL301203I2 (nl) | 2013-12-24 | 2022-11-03 | efgartigimod alfa |
Country Status (23)
Country | Link |
---|---|
US (3) | US10316073B2 (nl) |
EP (2) | EP3087095B1 (nl) |
JP (2) | JP6554473B2 (nl) |
KR (3) | KR20220152546A (nl) |
CN (2) | CN106103476B (nl) |
AU (1) | AU2014369999B2 (nl) |
BR (1) | BR112016014810B1 (nl) |
CA (1) | CA2934644C (nl) |
DK (1) | DK3087095T3 (nl) |
EA (1) | EA035324B1 (nl) |
ES (1) | ES2742682T3 (nl) |
FI (1) | FIC20230003I1 (nl) |
FR (1) | FR23C1004I2 (nl) |
HU (2) | HUE046822T2 (nl) |
IL (1) | IL246223B (nl) |
LT (2) | LT3087095T (nl) |
MX (1) | MX368804B (nl) |
NL (1) | NL301203I2 (nl) |
NZ (1) | NZ722055A (nl) |
PL (1) | PL3087095T3 (nl) |
PT (1) | PT3087095T (nl) |
SG (2) | SG11201605203UA (nl) |
WO (1) | WO2015100299A1 (nl) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3087095T (lt) | 2013-12-24 | 2019-09-10 | Argenx Bvba | Fcrn-antagonistai ir naudojimo būdai |
PL3268391T3 (pl) * | 2015-03-09 | 2022-01-03 | Argenx Bvba | Sposoby zmniejszania poziomów środków zawierających Fc w surowicy z zastosowaniem antagonistów FcRn |
FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
CN106957364B (zh) * | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb12及其应用 |
CN106957365B (zh) * | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
EP3257866A1 (en) * | 2016-06-17 | 2017-12-20 | Academisch Medisch Centrum | Modified anti-tnf antibody and use thereof in the treatment of ibd |
CN109689685A (zh) | 2016-07-08 | 2019-04-26 | 斯塔滕生物技术有限公司 | 抗apoc3抗体及其使用方法 |
GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
CA3045797A1 (en) * | 2016-12-02 | 2018-06-07 | The Texas A&M University System | Fusion proteins for selectively depleting antigen-specific antibodies |
WO2018193427A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
SG11202003980PA (en) | 2017-10-31 | 2020-05-28 | Staten Biotechnology B V | Anti-apoc3 antibodies and methods of use thereof |
BR112020011483A2 (pt) * | 2017-12-08 | 2020-11-24 | Argenx Bvba | uso de antagonistas de fcrn para tratamento de miastenia gravis generalizada |
SG11202011849VA (en) * | 2018-06-08 | 2020-12-30 | Argenx Bvba | Compositions and methods for treating immune thrombocytopenia |
BR112021000755A2 (pt) * | 2018-07-20 | 2021-04-13 | Momenta Pharmaceuticals, Inc. | Composições de anticorpo de fcrn |
WO2020054979A1 (ko) * | 2018-09-12 | 2020-03-19 | 아주대학교산학협력단 | Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물 |
GB2589049C (en) * | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
JOP20210298A1 (ar) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | طرق وتركيبات للوقاية من مرض السكري من النوع الأول |
CA3138072A1 (en) | 2019-06-07 | 2020-12-10 | Argenx Bvba | Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration |
CA3163172A1 (en) | 2020-01-08 | 2021-07-15 | Peter Verheesen | Methods for treating pemphigus disorders |
CN114341184B (zh) * | 2020-02-10 | 2023-04-04 | 北京拓界生物医药科技有限公司 | 抗FcRn抗体、其抗原结合片段及其医药用途 |
CN113769058A (zh) * | 2020-06-10 | 2021-12-10 | 上海宝济药业有限公司 | 一种药物组合及其应用 |
KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
EP4359432A2 (en) | 2021-06-23 | 2024-05-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Short apoc-ii mimetic peptides and methods of use |
WO2023139107A1 (en) | 2022-01-18 | 2023-07-27 | argenx BV | Galectin-10 antibodies |
TW202337895A (zh) | 2022-02-21 | 2023-10-01 | 比利時商阿根思公司 | 使用fcrn拮抗劑治療肌炎之方法 |
WO2023198806A1 (en) | 2022-04-13 | 2023-10-19 | Ose Immunotherapeutics | New class of molecules for selective clearance of antibody |
WO2023215838A1 (en) | 2022-05-05 | 2023-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Short apolipoprotein e mimetic peptides and methods of use |
CN115645537A (zh) * | 2022-10-25 | 2023-01-31 | 成都臻拓医药科技有限公司 | FcRn抑制剂在制备抑制自身免疫性疾病复发的药物中的用途 |
WO2024105445A2 (en) * | 2022-11-14 | 2024-05-23 | argenx BV | Fcrn antagonist molecules and methods of use thereof |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62153300A (ja) * | 1985-12-26 | 1987-07-08 | Teijin Ltd | ヒト免疫グロブリンGFc領域蛋白質およびその製造方法 |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
ATE331438T1 (de) | 1995-01-17 | 2006-07-15 | Brigham & Womens Hospital | Rezeptorspezifischer transepithelealer transport von immunogenen |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6128119A (en) | 1997-01-10 | 2000-10-03 | Asahi Kogaku Kogyo Kabushiki Kaisha | Beam shaping optical system |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CA2399832C (en) | 2000-02-11 | 2011-09-20 | Stephen D. Gillies | Enhancing the circulating half-life of antibody-based fusion proteins |
US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6992234B2 (en) | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
CA2856033C (en) | 2000-11-20 | 2015-11-03 | Canadian Blood Services | Use of a monoclonal antibody specific for a leukocyte to inhibit the reticuloendothelial system for the treatment of thrombocytopenia |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
JP3945281B2 (ja) | 2002-03-19 | 2007-07-18 | 富士ゼロックス株式会社 | 画像形成装置 |
US7351803B2 (en) | 2002-05-30 | 2008-04-01 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
US7425619B2 (en) | 2002-08-14 | 2008-09-16 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
EP2345671B8 (en) | 2002-09-27 | 2023-01-11 | Xencor, Inc. | Optimized fc variants and methods for their generation |
JP4768439B2 (ja) | 2002-10-15 | 2011-09-07 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のFcRn結合親和力又は血清半減期の改変 |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
BRPI0406662A (pt) | 2003-01-09 | 2005-12-20 | Macrogenics Inc | Vetor, célula, método de identificar um mab, e, composição |
CA2512974A1 (en) | 2003-01-13 | 2004-07-29 | Macrogenics, Inc. | Soluble fc.gamma.r fusion proteins and methods of use thereof |
US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
EP1798864A4 (en) | 2004-09-30 | 2013-07-31 | Brother Ind Ltd | WIRELESS LABEL COMMUNICATION DEVICE, WIRELESS LABEL, WIRELESS COMMUNICATION SYSTEM AND METHOD OF WIRELESS COMMUNICATION |
EP1879920A2 (en) | 2005-04-29 | 2008-01-23 | The Jackson Laboratory | Fcrn antibodies and uses thereof |
WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
WO2008131242A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
WO2008143954A2 (en) | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
EP3409687A1 (en) * | 2007-06-01 | 2018-12-05 | University of Maryland, Baltimore | Immunoglobulin constant region fc receptor binding agents |
US8195661B2 (en) | 2007-11-27 | 2012-06-05 | Umber Systems | Method and apparatus for storing data on application-level activity and other user information to enable real-time multi-dimensional reporting about user of a mobile data network |
US9260525B2 (en) * | 2008-02-04 | 2016-02-16 | Xiao-Jia Chang | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
US20110059091A1 (en) * | 2008-02-04 | 2011-03-10 | Xiao-Jia Chang | Inhibitors of oncogenic isoforms and uses thereof |
TWI593423B (zh) | 2008-04-25 | 2017-08-01 | 戴埃克斯有限公司 | Fc受體結合蛋白 |
US20100048488A1 (en) * | 2008-08-01 | 2010-02-25 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
SI2486141T1 (en) | 2009-10-07 | 2018-06-29 | Macrogenics, Inc. | FC REGION-CONTAINING POLYPETHYDE, AFFECTING A BETTERED EFFECTORAL FUNCTION, BY CHANGES IN THE SCOPE OF FUKOZILATION AND METHODS FOR THEIR USE |
GB201111291D0 (en) | 2011-06-30 | 2011-08-17 | Agco Int Gmbh | Engine control system |
EP2771694A4 (en) | 2011-10-26 | 2015-08-05 | Novartis Tiergesundheit Ag | MONOCLONAL ANTIBODIES AND METHOD FOR THEIR USE |
EP2780463A4 (en) * | 2011-11-18 | 2015-07-01 | Merck Sharp & Dohme | FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING |
KR102041412B1 (ko) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Fc 단편 유도체 |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
ES2743401T3 (es) | 2012-07-05 | 2020-02-19 | Hoffmann La Roche | Sistema de expresión y secreción |
KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
ES2909014T3 (es) | 2013-11-26 | 2022-05-04 | Brigham & Womens Hospital Inc | Composiciones y métodos para modular una respuesta inmunitaria |
LT3087095T (lt) | 2013-12-24 | 2019-09-10 | Argenx Bvba | Fcrn-antagonistai ir naudojimo būdai |
US10323066B2 (en) | 2014-09-17 | 2019-06-18 | Affibody Ab | Neonatal Fc receptor binding dimer and methods of use |
FI3250610T3 (fi) | 2015-01-30 | 2023-11-01 | Momenta Pharmaceuticals Inc | Fcrn-vasta-aineita ja menetelmiä niiden käyttämiseksi |
PL3268391T3 (pl) | 2015-03-09 | 2022-01-03 | Argenx Bvba | Sposoby zmniejszania poziomów środków zawierających Fc w surowicy z zastosowaniem antagonistów FcRn |
AU2016262100B2 (en) | 2015-05-12 | 2021-10-14 | Syntimmune, Inc. | Humanized affinity matured anti-FcRn antibodies |
GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
US10507234B2 (en) | 2015-07-17 | 2019-12-17 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with Fc-coupled antigens |
CN106957365B (zh) | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
GB201618424D0 (en) | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
BR112020011483A2 (pt) | 2017-12-08 | 2020-11-24 | Argenx Bvba | uso de antagonistas de fcrn para tratamento de miastenia gravis generalizada |
SG11202011849VA (en) | 2018-06-08 | 2020-12-30 | Argenx Bvba | Compositions and methods for treating immune thrombocytopenia |
EP3969125A4 (en) | 2019-05-17 | 2023-01-11 | Alexion Pharmaceuticals, Inc. | USE OF ANTI-FCRN ANTIBODIES IN THE TREATMENT OF PEMPHIGHUS AND PEMPHIGOID DISEASES |
-
2014
- 2014-12-23 LT LTEP14827372.5T patent/LT3087095T/lt unknown
- 2014-12-23 WO PCT/US2014/072087 patent/WO2015100299A1/en active Application Filing
- 2014-12-23 EA EA201691304A patent/EA035324B1/ru unknown
- 2014-12-23 SG SG11201605203UA patent/SG11201605203UA/en unknown
- 2014-12-23 HU HUE14827372A patent/HUE046822T2/hu unknown
- 2014-12-23 CN CN201480070435.1A patent/CN106103476B/zh active Active
- 2014-12-23 KR KR1020227034365A patent/KR20220152546A/ko not_active Application Discontinuation
- 2014-12-23 NZ NZ722055A patent/NZ722055A/en unknown
- 2014-12-23 US US14/580,771 patent/US10316073B2/en active Active
- 2014-12-23 KR KR1020167020339A patent/KR102452173B1/ko active IP Right Grant
- 2014-12-23 KR KR1020247006088A patent/KR20240033084A/ko active Search and Examination
- 2014-12-23 PL PL14827372T patent/PL3087095T3/pl unknown
- 2014-12-23 MX MX2016008399A patent/MX368804B/es active IP Right Grant
- 2014-12-23 BR BR112016014810-0A patent/BR112016014810B1/pt active IP Right Grant
- 2014-12-23 EP EP14827372.5A patent/EP3087095B1/en active Active
- 2014-12-23 AU AU2014369999A patent/AU2014369999B2/en active Active
- 2014-12-23 PT PT148273725T patent/PT3087095T/pt unknown
- 2014-12-23 EP EP19189186.0A patent/EP3626738A1/en active Pending
- 2014-12-23 JP JP2016542697A patent/JP6554473B2/ja active Active
- 2014-12-23 ES ES14827372T patent/ES2742682T3/es active Active
- 2014-12-23 DK DK14827372T patent/DK3087095T3/da active
- 2014-12-23 CN CN202010983097.8A patent/CN112142843A/zh active Pending
- 2014-12-23 SG SG10202009832XA patent/SG10202009832XA/en unknown
- 2014-12-23 CA CA2934644A patent/CA2934644C/en active Active
-
2016
- 2016-06-14 IL IL246223A patent/IL246223B/en unknown
-
2017
- 2017-11-22 US US15/821,104 patent/US11505585B2/en active Active
-
2019
- 2019-01-10 JP JP2019002272A patent/JP2019076103A/ja active Pending
-
2022
- 2022-02-15 US US17/672,346 patent/US20220275035A1/en active Pending
- 2022-11-03 NL NL301203C patent/NL301203I2/nl unknown
- 2022-11-15 LT LTPA2022014C patent/LTPA2022014I1/lt unknown
- 2022-11-21 HU HUS2200048C patent/HUS2200048I1/hu unknown
-
2023
- 2023-01-12 FR FR23C1004C patent/FR23C1004I2/fr active Active
- 2023-01-19 FI FIC20230003C patent/FIC20230003I1/fi unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FIC20230003I1 (fi) | Efgartigimodi alfa | |
DK3342773T3 (da) | Syk-hæmmere | |
DK3613453T3 (da) | Fordamper | |
UY4298S (es) | Carcasa | |
DK3077047T3 (da) | Aramcholsalte | |
DK3060460T3 (da) | Saddel | |
DK3027598T3 (da) | Oxoquinazolinyl-butanamidderivater | |
DK2956698T5 (da) | Bindestrimler | |
DK3052081T3 (da) | Pastil | |
DK2946640T3 (da) | Langmuir-probe | |
DK3071227T3 (da) | Fiskevaccine | |
DE102013106534B8 (de) | Chromatographiepipettenspitze | |
DE112014001252A5 (de) | Aufbissschiene | |
DK2981168T3 (da) | Laminitiskile | |
DK3086679T3 (da) | Sportssko | |
FI10138U1 (fi) | Kelkkateltta | |
ES1078715Y (es) | Mosquitera | |
DE112014005422A5 (de) | Friktionsfalschdrallaggregat | |
BR112016000501A2 (pt) | Nalador | |
UY4342S (es) | Carcasa | |
ES1100380Y (es) | Trompo | |
ES1093505Y (es) | Aerociclo | |
ES1096481Y (es) | Ecofregona | |
UY4316S (es) | Diseño celosías | |
ES1093455Y (es) | Columbario |